Related Experiment Videos
HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis
W W Wilkerson1, E Akamike, W W Cheatham
1DuPont Merck Pharmaceutical Company, E500/3203 Experimental Station, Wilmington, Delaware 19880-0500, USA.
Journal of Medicinal Chemistry
|October 11, 1996
Abstract:
A series of N,N'-disubstituted cyclic urea 3-benzamides has been synthesized and evaluated for HIV protease inhibition and antiviral activity. Some of these benzamides have been shown to be potent inhibitors of HIV protease with Ki < 0.050 nM and IC90 < 20 nM for viral replication and, as such, may be useful in the treatment of AIDS. The synthesis and quantitative structure-activity relationship for this benzamide series will be discussed.